Subscriber access provided by Kaohsiung Medical University

# ZnCl2-Catalyzed [3+2] Cycloaddition of Benzimidates and 2H-Azirines for the Synthesis of Imidazoles

Shoujie Shi, Kang Xu, Cheng Jiang, and Zhenhua DING

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.8b02437 • Publication Date (Web): 05 Nov 2018

# Downloaded from http://pubs.acs.org on November 8, 2018

# Just Accepted

Note

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

# ZnCl<sub>2</sub>-Catalyzed [3+2] Cycloaddition of Benzimidates and 2*H*-Azirines for the Synthesis of Imidazoles

Shoujie Shi, Kang Xu, Cheng Jiang, Zhenhua Ding\*

Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China. *Supporting Information Placeholder* 



**ABSTRACT:** ZnCl<sub>2</sub>-catalyed [3+2] cycloaddition reaction of benzimidates and 2*H*-azirines has been developed. This convenient method allowed the efficient construction of a serious of multi-substituted imidazoles in moderate to good yields under mild reaction conditions. This transformation exhibits good reactivity and high functional group tolerance.

2H-Azirine ring systems represent a highly important class of compounds found in natural products and biological active compounds.<sup>1</sup> Because of their high ring strain, 2*H*-azirines are also used as valuable building blocks in organic synthesis in the preparation of various N-heterocycles.<sup>2,3</sup> For example, the pyridines (Scheme 1a) synthesis via an Au-catalyzed ring-expansion of 2-propargyl 2H-azirine have been developed by Gagosz and co-workers.<sup>4</sup> The pyrroles (Scheme 1b)<sup>5</sup> and pyrazines (Scheme 1c)<sup>6</sup> synthesis from 2*H*-azirines catalyzed by Rh and Cu, respectively, have been reported by Park group. Synthesis of substituted imidazoles from 2H-azirine have also been investigated,<sup>7</sup> Leonard and co-worker reported the reaction of 2Hazirine and CH3CN in the presence of HClO4 to form imidazolium salt (Scheme 1d).<sup>7a</sup> Although much progress have been achieved in this area,<sup>8-11</sup> the development of new catalytic system for the construction of N-heterocycles using 2H-azirine as substrate under mild reaction conditions is still desirable. In this paper, we report a novel ZnCl<sub>2</sub>-catalyzed [3+2] cycloaddition reaction between benzimidates<sup>12</sup> and 2H-azirines for the synthesis of substituted imidzoles (Scheme 1e).

#### Scheme 1. Synthesis of N-Heterocycles from 2H-Azirines

(a) Au-catalyzed synthesis of pyridines



(b) Rh-catalyzed synthesis of pyrroles



#### (c) Cu-catalyzed synthesis of pyrazines



(d) synthesis of imidazolium salt from 2H-azirine







We commenced our investigation with the optimization studies on the [3+2] cycloaddition of ethyl benzimidate 1a and 3-(4-bromophenyl)-2H-azirine 2a (Table 1). The reaction provided expected product **3aa** in 67% yield in the presence of 10 mol% ZnCl<sub>2</sub> in dichloromethane (DCE) at 80 °C (entry 1). Other Lewis acid such as AlCl<sub>3</sub>, CoBr<sub>2</sub>, FeCl<sub>2</sub> and FeCl<sub>3</sub> also promoted this reaction, but with lower yields (entries 2-5). The reaction did not take place without Lewis acid catalyst (entry 6). The slight lower yields were obtained when using toluene or tetrahydrofuran (THF) as solvents (entries 7-8), while the reaction did not occur at all when methanol was employed (entry 9). The product yield was further improved to 74% when CH<sub>3</sub>CN<sup>7a</sup> was used instead of dichloromethane (entry 10). The use of lower temperature (60 °C or 25 °C) resulted in lower yields of 3aa (entries 11-12), while higher temperature (100 °C) did not increase the product yield (entry 13). The reaction didn't occur

60

Br

when HCl was used instead of  $ZnCl_2$  (entry 14). The gram scale reaction was performed and the product was obtained in 78% yield (entry 15).

#### Table 1. Optimization of Reaction Conditions<sup>a</sup>

NH Ph OEt	+ Br	Lewis ac solvent	id (10 mol%) ► , T, 12 h	Ph-V
1a	<b>2a</b> (1.2 equiv)			3aa
entry	Lewis acid	solvent	T (°C)	Yield <sup>b</sup> (%)
1	$ZnCl_2$	DCE	80	67
2	AlCl <sub>3</sub>	DCE	80	26
3	CoBr <sub>2</sub>	DCE	80	60
4	FeCl <sub>2</sub>	DCE	80	46
5	FeCl <sub>3</sub>	DCE	80	49
6	-	DCE	80	nr
7	$ZnCl_2$	toluene	80	66
8	$ZnCl_2$	THF	80	59
9	$ZnCl_2$	MeOH	80	nr
10	$ZnCl_2$	CH <sub>3</sub> CN	80	74
11	$ZnCl_2$	CH <sub>3</sub> CN	60	68
12	$ZnCl_2$	CH <sub>3</sub> CN	25	49
13	$ZnCl_2$	CH <sub>3</sub> CN	100	72
14	HC1	CH <sub>3</sub> CN	80	nr
15	$ZnCl_2$	CH <sub>3</sub> CN	80	78 <sup>c</sup>

<sup>*a*</sup> Reactions were carried out under atmosphere on a 0.3 mmol scale in solvent (1.5 mL). <sup>*b*</sup> Isolated yields. nr = no reaction. <sup>*c*</sup> The reaction was performed in 5 mmol scale.

After screening the reaction conditions, we examined the substrate scope of benzimidates 1 (Scheme 2). Benzimidates bearing electron-donating groups such as methoxy, methyl groups participated in this reaction well, and provided the corresponding products in 79-86% yields (3ba, 3ca, 3da). The electron-withdrawing group nitro and CF3 could be tolerated in the reaction conditions with moderate product yields (3ea and 3fa). Halogen substituents such as bromo, chloro and fluoro are tolerated well in the reaction conditions, the desired products were obtained in good yields (3ga, 3ha, 3ia). The reaction proceeded well when an acetyl group at the meta position of benzimidate and gave the product 3ja in 66% yield. The 2-naphthimidate substrate also underwent this reaction with good reactivity (3ka). A 4-phenyl substituted benzimidate underwent the cycloaddition reaction of 2a as smoothly as model substrate and afforded the expected product in 70% yield (3la). The reaction also proceeded well when indole-4-carbimidate was used as substrate and provided imidazolvl substituted indole in good yield (3ma). Furan-2-carbimidate and thiophene-2-carbimidate underwent the reaction well and afforded the corresponding imidazole in moderate yields (3na and 3oa). When the imidate with a benzyl substituent at 2-position, the reaction proceeded and gave the desired product 3pa in73% yield.

## Scheme 2. Scope of benzimidates<sup>*a,b*</sup>



<sup>*a*</sup> Reactions were carried out under atmosphere on a 0.3 mmol scale in solvent (1.5 mL). <sup>*b*</sup> Isolated yields.

The present reaction was applicable to a variety of 2*H*-azirines 2, as illustrated in Scheme 3. 3-Aryl-2*H*-azirine derivatives participated in this reaction and afforded the corresponding cycloaddition products 3aa-3ah in moderate to good yields. The substrates bearing bromo and chloro groups gave the products 3aa and 3ac, respectively, in 74% and 75% yields. The structure of 3aa was confirmed by X-ray crystal structure analysis.<sup>13</sup> The reaction proceeded well when the substrates bore electron-withdrawing groups such as fluoro and nitro groups afforded the products (3ac and 3ad) in good yields (87% and 82%). On the other hand, the reaction became sluggish with methyl, methoxy group and provided the products (3ae and 3af) in ca. 50% yield. Some functional groups such as formyl group could be tolerated in this reaction conditions and gave the annulation product 3ah in 46% yield. The 2,3-di-substituted 2H-azirines also underwent cycloaddition reaction to generate tri-substituted imidazoles. When 2H-azirine 2i was employed, the reaction proceeded well and afforded the imidazole products 3ai and 3ai' with 2.5:1 ratio in 71%. A thienyl-substituted 2H-azirine 2j also underwent the reaction with modest reactivity (3aj). Ethyl 3-phenyl-2H-azirine-2-carboxylate **3k** reacted with benzimidate **1a** to provide products 3ak and 3ak' with 1:1 ratio in moderate yield. When a fluoro was introduced to para position of benzene ring of the 2H-azirine, the products ratio was 1.4:1 with 52% yield (3al). The symmetric 2,3-diphenyl-2H-azirine also participated in this annulation reaction and afforded the corresponding product 3am in 78% yield.

#### Scheme 3. Scope of 2*H*-Azirines<sup>*a,b*</sup>

1

2

3

4

5

6 7 8

9 10 11

12 13

14 15

16

17

18

23

24

25

26

27

28

29

30

31

32 33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50 51

52

53

54

55

56

57

58 59

60



<sup>*a*</sup> Reactions were carried out under atmosphere on a 0.3 mmol scale in solvent (1.5 mL). <sup>*b*</sup> Isolated yields.

We then performed the reaction with addition of 1 equivalent of 2,2,6,6-Tetramethylpiperidine-1-oxyl (TEMPO) and product **3aa** was obtained in 71% (**Scheme 4a**). This experiment excluded the possibility of free radical reaction mechanism. Based on the previous reports and our data, we proposed the reaction mechanism of this transformation (**Scheme 4b**). First, in the presence of ZnCl<sub>2</sub>, the cationic azirine complex I was formed. Then complex I undergoes nucleophilic attack by benzimidate 1a to generate intermediate II. A subsequent ring opening and intramolecular nucleophilic attack of the N to the carbocation and OEt as a leaving group to form the five membered ring intermediate III. Finally, the elimination of ZnCl<sub>2</sub> catalyst to afford the imidazole product **3aa** and finish the catalytic cycle.

#### Scheme 4. Proposed Mechanism

(a) Reaction with radical scavenger TEMPO



In summary, we have developed a ZnCl<sub>2</sub>-catalyzed [3+2] cycloaddition reaction of benzimidates and 2*H*-azirines for the synthesis of substituted imidazoles. The reaction exhibits excellent reactivity, good functional group tolerance and moderate to good yields. Ongoing effort in our laboratory will explore the cycloaddition reaction to construct other heterocycles catalyzed by Lewis acid.

#### **EXPERIMENTAL SECTION**

General Experimental Methods. Unless otherwise noted, all chemicals were purchased from commercial suppliers and used without further purification. All reactions were performed by standard Schlenk techniques in oven-dried reaction vessels under air. Flash column chromatography was carried out using commercially available 300-400 mesh under pressure unless otherwise indicated. <sup>1</sup>H and <sup>13</sup>C nuclear magnetic resonance (NMR) spectra were recorded on a Bruker AV-300 (300 MHz) NMR spectrometer. <sup>1</sup>H and <sup>13</sup>C $\{^{1}H\}$  NMR spectra are reported in parts per million (ppm) downfield from an internal standard, tetramethylsilane (0 ppm), and DMSO-d6 ( $\delta$  H = 2.50 ppm;  $\delta$  C = 39.51 ppm), respectively. Infrared (IR) spectra were recorded using a thin film supported on KBr disks. High Resolution Mass measurement was performed on Agilent QTOF 6520 mass spectrometer with electron spray ionization (ESI) as the ion source. Anhydrous acetonitrile (MeCN) was distilled and stored over molecular sieves. Benzimidate derivatives 1 were prepared by following the same procedure as described in the literature.<sup>14</sup> 2H-azirines 2 were prepared by known procedure.<sup>15</sup>

General Procedure for ZnCl<sub>2</sub>-Catalyzed [3+2] Cycloaddition Reaction of Benzimidate and 2*H*-azirines. An ovendried Schlenk tube equipped with a magnetic stir bar was charged with ZnCl<sub>2</sub> (4.1 mg, 0.03 mmol, 10 mol %), benzimidate 1 (0.3 mmol, 1.0 equiv.), 2*H*-azirine 2 (0.36 mmol, 1.2 equiv). 1.5 mL CH<sub>3</sub>CN were successively added and then stirred at 80 °C for 12 h. The reaction mixture was allowed to cool down to room temperature and quenched with H<sub>2</sub>O (2 mL  $\times$  1) and extracted with ethyl acetate (5 mL  $\times$  3). The combined organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude mixture was purified by flash column chromatography (ethyl acetate/hexane) on silica gel and afforded corresponding imidazole **3**.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25 26

27

28

29

30

31

32

33

34

35 36

56

57

58 59

60

**5-(4-Bromophenyl)-2-phenyl-1H-imidazole (3aa):** A white solid; m.p. 169-171°C; Yield: 67 mg, 74%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.76 (s, 1H), 8.04 (d, *J* = 7.6 Hz, 2H), 7.85 (d, *J* = 8.0 Hz, 3H), 7.63 – 7.53 (m, 2H), 7.52 – 7.43 (m, 2H), 7.41 – 7.32 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  146.6, 140.4, 134.4, 131.8, 130.9, 129.2, 128.7, 126.8, 125.5, 119.4, 115.4; IR (KBr) vmax = 3421, 3168, 2926, 2843, 1658, 1485, 1458, 1301, 1140, 1069, 1051, 1025, 1007, 941, 830, 775, 694, 510 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>15</sub>H<sub>12</sub>BrN<sub>2</sub>: 299.0184, Found: 299.0180.

5-(4-Bromophenyl)-2-(4-methoxyphenyl)-1H-imidazole

(3ba): A white solid; m.p. 197-198°C; Yield: 78 mg, 79%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  7.97 (d, J = 8.7 Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 7.75 (s, 1H), 7.56 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.8 Hz, 2H), 3.81 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  159.9, 146.9, 131.8, 127.0, 126.8, 123.7, 119.3, 114.6, 55.7; IR (KBr) vmax = 3434, 2922, 2850, 2357, 1649, 1611, 1542, 1492, 1402, 1256, 1174, 1114, 1028, 1007, 938, 836, 774, 736, 617, 567, 505 cm<sup>-1</sup>;HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>16</sub>H<sub>14</sub>BrN<sub>2</sub>O: 329.0290, Found: 329.0285.

**5-(4-Bromophenyl)-2-(m-tolyl)-1H-imidazole (3ca):** A white solid; Yield: 78 mg, 81%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.70 (s, 1H), 7.99 – 7.71 (m, 5H), 7.58 (d, J = 7.6 Hz, 2H), 7.40 – 7.32 (m, 1H), 7.19 (d, J = 6.8 Hz, 1H), 2.39 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  146.9, 138.4, 131.9, 130.9, 129.4, 129.1, 126.8, 126.1, 122.7, 119.4, 21.6; IR (KBr) vmax = 3426, 3154, 2921, 2852, 1660, 1612, 1483, 1401, 1324, 1138, 1069, 1008, 943, 830, 791, 726, 690, 503 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>16</sub>H<sub>14</sub>BrN<sub>2</sub>: 313.0340, Found: 313.0339.

### 5-(4-Bromophenyl)-2-(3,5-dimethylphenyl)-1*H*-imidazole

37 (3da): A white solid; m.p. 197-199°C; Yield: 86 mg, 86%; <sup>1</sup>H 38 NMR (300 MHz, DMSO-d6)  $\delta$  12.65 (s, 1H), 7.83 (d, J = 7.839 Hz, 2H), 7.77 (s, 1H), 7.66 (s, 2H), 7.57 (d, J = 7.4 Hz, 2H), 6.99 (s, 1H), 2.34 (s, 6H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSOd6) 40 δ 147.0, 138.2, 131.8, 130.8, 130.2, 127.5, 127.0, 126.8, 126.2, 41 123.3, 119.4, 21.5; IR (KBr) vmax = 3447, 3197, 2920, 2843, 42 1654, 1605, 1478, 1402, 1025, 1007, 852, 827, 766, 732, 688, 43 507 cm<sup>-1</sup>; HRMS (ESI) m/z  $[M+H]^+$ : Calcd for C<sub>17</sub>H<sub>16</sub>BrN<sub>2</sub>: 44 327.0497, Found: 327.0498. 45

46 5-(4-Bromophenyl)-2-(4-nitrophenyl)-1*H*-imidazole (3ea): 47 A yellow solid; m.p. 206-207°C; Yield: 56 mg, 54%; <sup>1</sup>H NMR 48  $(300 \text{ MHz}, \text{DMSO-d6}) \delta 13.18 (s, 1H), 8.33 (d, J = 8.9 \text{ Hz}, 2H),$ 8.27 - 8.18 (m, 2H), 7.99 (s, 1H), 7.89 - 7.80 (m, 2H), 7.58 (d, 49 J = 8.5 Hz, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  147.1, 50 144.6, 141.7, 136.7, 134.0, 132.0, 127.1, 126.1, 124.8, 120.0, 51 117.4; IR (KBr) vmax = 3401, 3178, 2923, 2852, 1646, 1603, 52 1508, 1482, 1402, 1339, 1152, 1109, 1069, 1008, 854, 833, 767, 53 717, 501 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for 54  $C_{15}H_{11}BrN_{3}O_{2}$ : 344.0035, Found:. 344.0034. 55

**5-(4-Bromophenyl)-2-(4-(trifluoromethyl)phenyl)-1***H***-imid-azole (3fa):** A white solid; m.p. 190-191°C; Yield: 69 mg, 63%;

<sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  13.03 (s, 1H), 8.21 (d, J = 8.2 Hz, 2H), 7.90 (s, 1H), 7.84 (d, J = 8.5 Hz, 4H), 7.58 (d, J = 8.4 Hz, 2H); 13C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  145.2, 134.5, 131.9, 128.6 (q, <sup>2</sup> $J_{C-H}=$  31.8 Hz), 128.0, 126.9, 126.5, 126.3, 126.2, 125.9, 122.9, 119.8; IR (KBr) vmax = 3421, 3193, 2924, 2849, 1620, 1442, 1327, 1167, 1124, 1065, 1026, 1009, 849, 823, 504 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>16</sub>H<sub>11</sub>BrF<sub>3</sub>N<sub>2</sub>: 367.0058, Found: 367.0047.

**2,5-Bis(4-bromophenyl)-1***H***-imidazole (3ga):** A white solid; m.p. 203-205°C; Yield: 64 mg, 66%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.83 (s, 1H), 7.96 (d, *J* = 8.5 Hz, 2H), 7.90 – 7.75 (m, 3H), 7.68 (d, *J* = 8.5 Hz, 2H), 7.57 (d, *J* = 8.4 Hz, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  145.6, 132.1, 131.8, 130.0, 127.3, 126.8, 121.8, 119.7; IR (KBr) vmax = 3449, 3231, 2922, 2850, 1647, 1482, 1431, 1291, 1152, 1072, 1009, 943, 829, 780, 725, 503 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>15</sub>H<sub>11</sub>Br<sub>2</sub>N<sub>2</sub>: 376.9289, Found: 376.9288.

#### 5-(4-Bromophenyl)-2-(4-chlorophenyl)-1*H*-imidazole

(3ha): A yellow solid; m.p. 198-200°C; Yield: 71 mg, 71%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.83 (s, 1H), 8.02 (d, J = 8.3Hz, 2H), 7.91 – 7.78 (m, 3H), 7.63 – 7.47 (m, 4H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  133.3, 131.9, 129.7, 129.4, 128.8, 127.4, 127.2, 127.0, 126.8; IR (KBr) vmax = 3434, 3178, 2922, 2851, 2353, 1655, 1596, 1483, 1399, 1271, 1092, 1069, 1009, 944, 833, 762, 731, 501 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>15</sub>H<sub>11</sub>BrClN<sub>2</sub>: 332.9794, Found: 332.9794.

**5-(4-Bromophenyl)-2-(4-fluorophenyl)-1***H*-imidazole (3ia): A yellow solid; Yield: 69 mg, 73%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.75 (s, 1H), 8.20 – 7.98 (m, 2H), 7.96 – 7.73 (m, 3H), 7.68 –7.50 (m, 2H), 7.43 – 7.23 (m, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  162.6 (d, <sup>1</sup>*J*<sub>C-F</sub>= 245.4 Hz), 145.8, 140.4, 134.4, 131.8, 127.6 (d, <sup>3</sup>*J*<sub>C-F</sub>= 3.4 Hz), 126.8, 119.4, 116.2 (d, <sup>2</sup>*J*<sub>C-F</sub>= 21.9 Hz), 115.4; IR (KBr) vmax = 3421, 2921, 2851, 1612, 1503, 1444, 1400, 1247, 1147, 1072, 1008, 964, 833, 769, 739, 615, 532 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>15</sub>H<sub>11</sub>BrFN<sub>2</sub>: 317.0090, Found: 317.0088.

### 1-(3-(5-(4-Bromophenyl)-1H-imidazol-2-yl)phenyl)etha-

**none (3ja):** A white solid; m.p. 223-224°C; Yield: 68 mg, 66%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.94 (s, 1H), 8.59 (s, 1H), 8.27 (d, J = 7.8 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.81 (dd, J =24.7, 8.2 Hz, 3H), 7.64 (t, J = 7.8 Hz, 1H), 7.58 (d, J = 8.4 Hz, 2H), 2.66 (s, 3H). <sup>13</sup>C {<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  198.3, 137.8, 131.9, 131.3, 129.8, 129.7, 128.4, 126.9, 124.9, 27.3; IR (KBr) vmax = 3428, 3202, 2919, 2851, 1663, 1473, 1445, 1404, 1260, 1139, 1024, 1007, 943, 834, 754, 727, 683, 595 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>17</sub>H<sub>13</sub>BrN<sub>2</sub>O: 341.0290, Found: 341.0285.

#### 5-(4-Bromophenyl)-2-(naphthalen-2-yl)-1H-imidazole

(3ka): A gray solid; m.p. 206-207°C; Yield: 78 mg, 74%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.93 (s, 1H), 8.55 (s, 1H), 8.21 (d, *J* = 8.5 Hz, 1H), 8.05 – 7.86 (m, 6H), 7.64 – 7.50 (m, 4H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  133.5, 133.2, 131.9, 128.8, 128.6, 128.4, 128.2, 127.2, 126.9, 124.0, 123.8; IR (KBr) vmax = 3533, 3229, 3193, 2920, 2850, 2616, 2360, 1657, 1598, 1478, 1410, 1292, 1149, 1132, 1070, 1006, 950, 864, 825, 751, 489 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>19</sub>H<sub>14</sub>BrN<sub>2</sub>: 349.0340, Found: 349.0338. 

# 2-([1,1'-Biphenyl]-4-yl)-5-(4-bromophenyl)-1*H*-imidazole

(31a): A yellow solid; m.p.  $251-253^{\circ}$ C; Yield: 80 mg, 70%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.83 (s, 1H), 8.13 (d, J = 8.3 Hz, 2H), 7.88 (d, J = 8.2 Hz, 3H), 7.79 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 7.3 Hz, 2H), 7.58 (d, J = 8.4 Hz, 2H), 7.48 (t, J = 7.5 Hz, 2H), 7.38 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  133.5, 133.2, 131.9, 128.8, 128.6, 128.4, 128.2, 127.2, 126.9, 126.8, 124.0, 123.8; IR (KBr) vmax = 3414, 2921, 2851, 1646, 1483, 1422, 1401, 1128, 1107, 1079, 1067, 1007, 942, 837, 767, 732, 690, 561, 504 cm<sup>-1</sup>;HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>21</sub>H<sub>16</sub>BrN<sub>2</sub>: 375.0497, Found: 375.0498.

# 4-(5-(4-Bromophenyl)-1*H*-imidazol-2-yl)-1-methyl-1*H*-in-

**dole (3ma):** A yellow solid; Yield: 82 mg, 77%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.64 (s, 1H), 7.91 (d, J = 8.5 Hz, 2H), 7.83 (s, 1H), 7.65 (d, J = 7.2 Hz, 1H), 7.62 – 7.58 (m, 2H), 7.49 – 7.42 (m, 3H), 7.29 – 7.22 (m, 1H), 3.83 (s, 3H); <sup>13</sup>C {<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  147.5, 137.7, 131.9, 130.6, 126.8, 125.4, 122.5, 121.3, 119.3, 116.9, 110.5, 102.7, 33.1; IR (KBr) vmax = 3398, 3132, 2922, 2849, 2360, 1901, 1723, 1657, 1598, 1512, 1485, 1449, 1417, 1333, 1286, 1119, 1065, 1018, 1006, 943, 831, 752, 509 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>18</sub>H<sub>15</sub>BrN<sub>3</sub>: 352.0449, Found: 352.0450.

**5-(4-Bromophenyl)-2-(furan-2-yl)-1***H***-imidazole (3na):** A yellow solid; m.p. 209-210°C; Yeild: 49mg, 56%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.77 (s, 1H), 7.78 (d, *J* = 6.6 Hz, 4H), 7.55 (d, *J* = 8.3 Hz, 2H), 6.91 (d, *J* = 3.2 Hz, 1H), 6.68-6.58 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  145.8, 142.9, 131.4, 126.3, 119.0, 111.8, 107.0; IR (KBr) vmax = 3414, 3229, 2923, 2852, 1637, 1618, 1521, 1483, 1475, 1400, 1289, 1173, 1150, 1108, 1070, 1019, 1006, 983, 890, 813, 765, 731, 640, 596, 501 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>13</sub>H<sub>10</sub>BrN<sub>2</sub>O: 288.9977, Found: 288.9973.

**5-(4-Bromophenyl)-2-(thiophen-2-yl)-1***H***-imidazole** (30a): A white solide; m.p. 212-213°C; Yeild: 55mg, 60%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.74 (s, 1H), 7.77 (d, *J* = 6.9 Hz, 1H), 7.59 – 7.50 (m, 2H), 7.17 – 7.09 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  142.6, 140.1, 134.5, 134.1, 131.8, 128.3, 126.8, 126.6, 124.4, 119.4, 114.9; IR (KBr) vmax = 3552, 3475, 3414, 3110, 2921, 1640, 1617, 1496, 1476, 1419, 1227, 1139, 1084, 1064, 1008, 947, 930, 847, 830, 781, 726, 698, 624, 502, 481 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>13</sub>H<sub>10</sub>BrN<sub>2</sub>S: 304.9748, Found: 304.9746.

**2-Benzyl-5-(4-bromophenyl)-1***H***-imidazole (3pa):** A yellow oil; Yeild: 69mg, 73%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.05 (s, 1H), 7.67 (d, *J* = 8.5 Hz, 2H), 7.55 – 7.45 (m, 3H), 7.33 – 7.15 (m, 5H), 4.00 (s, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  147.7, 138.9, 131.7, 128.9, 128.8, 126.7, 126.5, 118.9, 34.7; IR (KBr) vmax = 3413, 3137, 2923, 2853, 2360, 2342, 1637, 1617, 1535, 1493, 1477, 1454, 1399, 1135, 1069, 1008, 952, 829, 772, 726, 693, 506 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>16</sub>H<sub>14</sub>BrN<sub>2</sub>: 313.0340, Found: 313.0336.

5-(4-Chlorophenyl)-2-phenyl-1H-imidazole (3ab): A green solid; m.p. 156-158°C; Yield: 58 mg, 75%; <sup>1</sup>H NMR (300 MHz, DMSO-d6) δ 12.75 (s, 1H), 8.03 (d, J = 7.5 Hz, 2H), 7.90 (d, J = 8.2 Hz, 2H), 7.84 (s, 1H), 7.54 – 7.41 (m, 4H), 7.40 – 7.34 (m, 1H);  ${}^{13}C{}^{1}H$  NMR (75 MHz, DMSO-d6)  $\delta$  146.6, 140.4, 134.1, 130.9, 129.2, 128.9, 128.7, 126.5, 125.4, 115.4; IR (KBr) vmax = 3428, 3138, 2920, 2843, 1648, 1486, 1458, 1410, 1295, 1091, 1026, 1011, 941, 827, 781, 709, 695, 582, 514, 501 cm<sup>-1</sup>; 

HRMS (ESI) m/z  $[M+H]^+$ : Calcd for  $C_{15}H_{12}ClN_2$ : 255.0689, Found: 255.0688.

**5-(4-Fluorophenyl)-2-phenyl-1***H***-imidazole (3ac):** A green solid; m.p. 169-170°C; Yield: 63 mg, 87%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.69 (s, 1H), 8.02 (d, *J* = 7.4 Hz, 2H), 7.90 (dd, *J* = 8.4, 5.7 Hz, 2H), 7.75 (s, 1H), 7.53 – 7.43 (m, 2H), 7.41 – 7.32 (m, 1H), 7.23 (t, *J* = 8.8 Hz, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  161.4 (d, <sup>1</sup>*J*<sub>C-F</sub> = 242.4 Hz), 146.4, 131.0, 129.2, 128.6, 126.7 (d, <sup>3</sup>*J*<sub>C-F</sub> = 7.9 Hz), 125.4, 115.8 (d, <sup>2</sup>*J*<sub>C-F</sub> = 21.7 Hz); IR (KBr) vmax = 3445, 3144, 2923, 2843, 2360, 1658, 1607, 1566, 1497, 1462, 1459, 1402, 1232, 1156, 1025, 838, 774, 693, 602, 513 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>15</sub>H<sub>12</sub>FN<sub>2</sub>: 239.0985, Found: 239.0982.

**5-(4-Nitrophenyl)-2-phenyl-1***H***-imidazole (3ad):** A yellow solid; m.p. 178-179°C; Yield: 66 mg, 82%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  13.00 (s, 1H), 8.25 (d, *J* = 8.9 Hz, 2H), 8.11 (d, *J* = 8.4 Hz, 3H), 8.05 (d, *J* = 7.5 Hz, 2H), 7.54 – 7.45 (m, 2H), 7.43 – 7.35 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  147.5, 145.7, 141.8, 139.6, 130.5, 129.3, 129.1, 125.6, 125.2, 124.6, 118.5; IR (KBr) vmax = 3519, 3108, 2923, 2852, 2363, 1655, 1600, 1511, 1330, 1182, 1143, 1111, 858, 788, 752, 713, 689, 486 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>15</sub>H<sub>12</sub>N<sub>3</sub>O<sub>2</sub>: 266.0930, Found: 266.0928.

**2-Phenyl-5-**(*p*-tolyl)-1*H*-imidazole (3ae): A white solid; m.p. 168-170°C; Yield: 35 mg, 50%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.61 (s, 1H), 8.03 (d, *J* = 7.4 Hz, 2H), 7.76 (d, *J* = 8.0 Hz, 2H), 7.66 (s, 1H), 7.52 – 7.43 (m, 2H), 7.40 – 7.32 (m, 1H), 7.23 – 7.16 (m, 2H), 2.31 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  146.3, 135.9, 131.1, 129.6, 129.2, 128.5, 125.4, 124.8, 21.3; IR (KBr) vmax = 3424, 3162, 2921, 2849, 2259, 1655, 1607, 1499, 1459, 1405, 1298, 1179, 1143, 1045, 1025, 1006, 822, 774, 693, 507 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>16</sub>H<sub>15</sub>N<sub>2</sub>: 235.1235, Found: 235.1230.

**5-(4-Methoxyphenyl)-2-phenyl-1***H***-imidazole (3af):** A yellow solid. Yield: 33 mg, 43%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  8.01 (d, J = 7.4 Hz, 2H), 7.78 (d, J = 8.7 Hz, 2H), 7.59 (s, 1H), 7.51 – 7.43 (m, 2H), 7.40 – 7.31 (m, 1H), 6.97 (d, J = 8.8 Hz, 2H), 3.78 (s, 3H); <sup>13</sup>C {<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  158.5, 146.2, 131.1, 129.2, 128.5, 126.2, 125.3, 114.4, 55.5; IR (KBr) vmax = 3392, 3162, 2921, 2843, 1604, 1499, 1460, 1247, 1178, 1027, 833, 774, 708, 693, 610, 524 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>16</sub>H<sub>15</sub>N<sub>2</sub>O: 251.1184, Found: 251.1184.

**2,5-Diphenyl-1***H***-imidazole (3ag):** A white solid; Yield: 31 mg, 47%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.67 (s, 1H), 8.03 (d, *J* = 7.3 Hz, 2H), 7.87 (d, *J* = 7.3 Hz, 2H), 7.73 (s, 1H), 7.53 – 7.44 (m, 2H), 7.43 – 7.34 (m, 3H), 7.27 – 7.19 (m, 1H); <sup>13</sup>C {<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  146.5, 131.1, 129.2, 129.0, 128.6, 128.4, 126.8, 125.4, 125.1, 125.0, 124.9; IR (KBr) vmax = 3463, 3144, 2923, 2852, 1646, 1606, 1488, 1459, 1401, 1143, 1072, 1024, 1006, 822, 773, 757, 692, 501 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]+: Calcd for C<sub>15</sub>H<sub>13</sub>N<sub>2</sub>: 221.1079, Found: 221.1077.

**4-(2-Phenyl-1***H***-imidazol-5-yl)benzaldehyde (3ah):** A yellow solid, m.p. 168-169°C; Yield: 35 mg, 46%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.93 (s, 1H), 9.98 (s, 1H), 8.18 – 7.99 (m, 5H), 7.94 (d, *J* = 8.2 Hz, 2H), 7.56 – 7.44 (m, 2H), 7.44 – 7.35 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  192.7, 147.1, 141.1, 140.4, 134.5, 130.7, 130.6, 129.3, 128.9, 125.6, 125.1, 117.6; IR (KBr) vmax = 3455, 3324, 3287, 2921, 2850, 1683,

1601, 1458, 1424, 1395, 1303, 1215, 1165, 1127, 1026, 943, 834, 775, 698, 649, 507 cm<sup>-1</sup>; HRMS (ESI) m/z  $[M+H]^+$ : Calcd for C<sub>16</sub>H<sub>13</sub>N<sub>2</sub>O: 249.1028, Found: 249.1025.

**Ethyl 5-methyl-2-phenyl-1***H***-imidazole-4-carboxylate (3ai):** Obtained as a 2.5:1 mixture with its regioisomer ethyl 4-methyl-2-phenyl-1*H*-imidazole-5-carboxylate (**3ai**'); A white solid; m.p. 197-198°C; Yield: 50 mg, 71%; <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 12.99 (s, 1H, **3ai**'), 12.85 (s, 1H, **3ai**), 8.12 (d, *J* = 6.6 Hz, 2H, **3ai**'), 7.93 (d, *J* = 7.5 Hz, 2H, **3ai**), 7.50 – 7.36 (m, 3H, **3ai** and **3ai**'), 4.30 – 4.21 (m, 2H, **3ai** and **3ai**') 2.51 (s, 3H, **3ai**), 2.42 (s, 3H, **3ai**'), 1.31 – 1.27 (m, 3H, **3ai** and **3ai**'); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, DMSO-d6) δ 163.8, 160.8, 147.8, 146.6, 144.8, 137.1, 130.3, 129.6, 129.3, 129.1, 128.9, 126.6, 125.5, 60.4, 59.9, 59.7, 15.1, 14.9, 11.6; IR (KBr) vmax = 3466, 2978, 2345, 1707, 1597, 1535, 1491, 1458, 1400, 1320, 1213, 1112, 1100, 1024, 972, 783, 708, 618, 465 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>13</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub>: 231.1134, Found: 231.1131.

tert-Butyl-2-phenyl-5-(thiophen-2-yl)-1H-imidazole-4-car-

**boxylate (3aj):** A yellow solid; Yield: 32 mg, 32%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$  12.97 (s, 1H), 8.16 (d, J = 6.6 Hz, 2H), 8.04 – 7.99 (m, 1H), 7.60 – 7.56 (m, 1H), 7.54 – 7.46 (m, 3H), 7.15 (dd, J = 5.0, 3.8 Hz, 1H), 1.61 (s, 9H); <sup>13</sup>C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  159.8, 147.9, 140.8, 137.3, 130.1, 129.4, 129.1, 127.9, 127.9, 127.3, 127.0, 119.3, 82.3, 28.5; IR (KBr) vmax = 3439, 3071, 2977, 2926, 2851, 1700, 1563, 1506, 1480, 1453, 1433, 1393, 1367, 1300, 1170, 1111, 1047, 1021, 847, 780, 694 cm<sup>-1</sup>; HRMS (ESI) m/z [M+H]<sup>+</sup>: Calcd for C<sub>18</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S: 327.1167, Found: 327.1167.

Ethyl-2,5-diphenyl-1H-imidazole-4-carboxylate (3ak): Obtained as a 1:1 mixture with its regioisomer Ethyl-2,4-diphenyl-1H-imidazole-5-carboxylate (3ak'); A yellow solid; m.p. 167-169°C; Yield: 37 mg, 41%; <sup>1</sup>H NMR (300 MHz, DMSO-d6) δ 13.23 (s, 1H, **3ak**), 13.09 (s, 1H, **3ak**'), 8.21 (d, J = 6.5 Hz, 1H, **3ak** and **3ak**'), 8.08 (d, J = 6.8 Hz, 1H, **3ak** and **3ak**'), 7.91 (d, J = 6.4 Hz, 1H, **3ak** and **3ak**'), 7.73 – 7.66 (m, 1H, **3ak** and **3ak'**), 7.54 – 7.36 (m, 6H, **3ak** and **3ak'**), 4.34 – 4.15 (m, 2H, **3ak** and **3ak**'), 1.31 - 1.15 (m, 3H, **3ak** and **3ak**');  ${}^{13}C{}^{1}H{}$ NMR (75 MHz, DMSO-d6) & 165.71, 163.34, 160.41, 148.31, 147.45, 146.3, 130.1, 129.7, 129.2, 129.0, 128.3, 128.1, 126.9, 126.1, 119.3, 60.8, 60.0, 14.6; IR (KBr) vmax = 3428, 2921,2850, 2357, 1712, 1531, 1487, 1474, 1381, 1311, 1258, 1265, 1235, 1129, 1023, 997, 966, 780, 762, 717, 693 cm<sup>-1</sup>; HRMS (ESI) m/z  $[M+H]^+$ : Calcd for C<sub>18</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub>: 293.1290, Found: 293.1290.

44 Ethyl-5-(4-fluorophenyl)-2-phenyl-1H-imidazole-4-carbox-45 vlate (3al): Obtained as a 1.4:1 mixture with its regioisomer 46 Ethyl-4-(4-fluorophenyl)-2-phenyl-1H-imidazole-5-carbox-47 ylate (3al'); A white solid; m.p. 206-207°C; Yield: 49 mg, 52%; 48 <sup>1</sup>H NMR (300 MHz, DMSO-d6) δ 13.23 (s, 1H, **3al**), 13.09 (s, 49 1H, **3al'**), 8.20 (d, J = 6.6 Hz, 2H, **3al**), 8.07 (d, J = 7.3 Hz, 2H, **3al'**), 7.97 (dd, J = 8.7, 5.8 Hz, 2H, **3al**), 7.75 (dd, J = 8.6, 5.6 50 Hz, 2H, 3al'), 7.55 – 7.40 (m, 5H, 3al), 7.41 – 7.22 (m, 5H, 51 **3al'**), 4.30 (q, J = 7.1 Hz, 2H, **3al**), 4.20 (q, J = 7.1 Hz, 2H, 52 **3al'**), 1.28 (t, *J* = 7.1 Hz, 3H, **3al**), 1.21 (t, *J* = 7.0 Hz, 3H, **3al'**); 53 13C{<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  164.2 (d, <sup>2</sup>*J*<sub>C-F</sub> = 22.2 54 Hz), 163.3, 161.0 (d,  ${}^{2}J_{C-F}$  = 21.6 Hz), 160.0, 148.3, 146.4, 55 146.3, 137.7, 132.4 (d,  ${}^{3}J_{C-F} = 8.3 \text{ Hz}$ ), 131.7 (d,  ${}^{3}J_{C-F} = 8.3 \text{ Hz}$ ), 56 130.7 (d,  ${}^{4}J_{C-F} = 3.0$  Hz), 130.1, 130.0, 129.7, 129.4, 129.23, 57 129.15, 128.9, 126.9, 126.4 (d,  ${}^{4}J_{C-F} = 3.3$  Hz), 126.1, 119.3, 58

115.4, 115.1, 115.0, 114.8, 60.9, 60.0, 14.61, 14.56. IR (KBr) vmax = 3452, 3074, 2922, 2851, 1710, 1607, 1533, 1503, 1485, 1474, 1381, 1316, 1230, 1158, 1130, 1023, 965, 842, 789, 715, 703 cm<sup>-1</sup>; HRMS (ESI) m/z[M+H]<sup>+</sup>: Calcd for  $C_{18}H_{16}FN_2O_2$ : 311.1196, Found: 311.1188.

**2,4,5-Triphenyl-1***H***-imidazole(3am):** A white solid; m.p. 274-275°C; Yield: 70 mg, 78%; <sup>1</sup>H NMR (300 MHz, DMSO-d6)  $\delta$ 12.74 (s, 1H), 8.13 (d, *J* = 7.3 Hz, 2H), 7.56 (d, *J* = 7.2 Hz, 4H), 7.49 (t, *J* = 7.5 Hz, 2H), 7.44 – 7.23 (m, 7H); <sup>13</sup>C {<sup>1</sup>H} NMR (75 MHz, DMSO-d6)  $\delta$  146.0, 130.8, 129.2, 128.9, 128.7, 128.6-127.1(m), 125.7; IR (KBr) vmax = 3434, 3037, 2963, 2920, 2851, 2363, 1600, 1488, 1460, 1460, 1396, 1127, 1070, 1027, 965, 915, 840, 765, 736, 697, 495 cm<sup>-1</sup>; HRMS (ESI) m/z[M+H]<sup>+</sup>: Calcd for C<sub>21</sub>H<sub>17</sub>N<sub>2</sub>: 297.1392, Found: 297.1383.

## ASSOCIATED CONTENT

#### **Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website. <sup>1</sup>H and <sup>13</sup>C NMR spectra for all the products (PDF) X-ray crystallographic data for **3aa** (CIF)

# AUTHOR INFORMATION

#### **Corresponding Author**

\*zhding@cpu.edu.cn

### Notes

The authors declare no competing financial interest.

# ACKNOWLEDGMENT

Financial support from the National Natural Science Foundation of China (NSFC 81602952), the Natural Science Foundation of Jiangsu Province (BK20160748), the Project Program of Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University (2018KFKT-3) is acknowledged.

### REFERENCES

(1) (a) Skepper, C. K.; Molinski, T. F. Long-Chain 2*H*-Azirines with Heterogeneous Terminal alogenation from the Marine Sponge *Dysidea fragilis. J. Org. Chem.* **2008**, *73*, 2592-2597. (b) Skepper, C. K.; Dalisay, D. S.; Molinski, T. F. Synthesis and Chain-Dependent Antifungal Activity of Long-Chain 2*H*-Azirine-Carboxylate Esters Related to Dysidazirine. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2029-2032.

(2) For reviews, see: (a) Palacios, F.; de Retana, A.; de Marigorta, E. M.; de los Santos, J. M. 2*H*-Azirines as Synthetic Tools in Organic Chemistry. *Eur. J. Org. Chem.* **2001**, 2001, 2401-2414. (b) Palacios, F.; de Retana, A. M. O.; Martínez de Marigorta, E.; Manuel de los Santos, J. Preparation, Properties and Synthetic Application of 2*H*-Azirines A Review. *Org. Prep. Proced. Int.* **2002**, *34*, 219-269. (c) Balme, G. Pyrrole Syntheses by Multicomponent Coupling Reactions. *Angew. Chem., Int. Ed.* **2004**, *43*, 6238-6241. (d) Khlebnikov, A. F.; Novikov, M. S. Recent Advances in 2*H*-Azirine Chemistry. *Tetrahedron* **2013**, *69*, 3363-3401. (e) Huang, C.-Y.; Doyle, A. G. The Chemistry of Transition Metals with Three-Membered Ring Heterocycles. *Chem. Rev.* **2014**, *114*, 8153-8198. (f) Ouyang, K.; Hao, W.; Zhang, W.-X.; Xi, Z. Transition-Metal-Catalyzed Cleavage of C–N Single Bonds. *Chem. Rev.* **2015**, *115*, 12045-12090.

(3) For recent contributions, see: (a) Xuan, J.; Xia, X.-D.; Zeng, T.-T.; Feng, Z.-J.; Chen, J.-R.; Lu, L.-Q.; Xiao, W.-J. Visible-Light-Induced Formal [3+2] Cycloaddition for Pyrrole Synthesis under Metal-

59 60 1

2

3

4

5

6

7

8

9

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

60

Free Conditions. Angew. Chem., Int. Ed. 2014, 53, 5653-5656. (b) Mueller, J. O.; Schmidt, F. G.; Blinco, J. P.; Barner-Kowollik, C. Visible-Light-Induced Click Chemistry. Angew. Chem., Int. Ed. 2015, 54, 10284-10288. (c) Zeng, T.-T.; Xuan, J.; Ding, W.; Wang, K.; Lu, L.-Q.; Xiao, W.-J. [3 + 2] Cycloaddition/Oxidative Aromatization Seguence via Photoredox Catalysis: One-Pot Synthesis of Oxazoles from 2H-Azirines and Aldehydes. Org. Lett. 2015, 17, 4070-4073. (d) Jin, L.; Wu, Y.; Zhao, X. Theoretical Insight into the Mechanism of Gold(I)-Catalyzed Rearrangement of 2-Propargyl 2H-Azirines to Pyridines. J. Org. Chem. 2015, 80, 3547-3555. (e) Li, T.; Xu, F.; Li, X.; Wang, C.; Wan, B. Ruthenium-Catalyzed C-C Bond Cleavage of 2H-Azirines: A Formal [3+2+2] Cycloaddition to Fused Azepine Skeletons. Angew. Chem., Int. Ed. 2016, 55, 2861-2865. (f) Zhao, M.-N.; 10 Zhang, M.-N.; Ren, Z.-H.; Wang, Y.-Y.; Guan, Z.-H. Base-mediated 11 Formal [3+2] Cycloaddition of  $\beta$ , $\gamma$ -Alkenyl Esters and p-TsN3 for the 12 Synthesis of Pyrazoles. Sci. Bull. 2017, 62, 493-496. 13

(4) Prechter, A.; Henrion, G.; Faudot dit Bel, P. F.; Gagosz, F. Gold-Catalyzed Synthesis of Functionalized Pyridines by Using 2H-Azirines as Synthetic Equivalents of Alkenyl Nitrenes. Angew. Chem., Int. Ed. 2014, 53, 4959-4963.

(5) Jiang, Y.; Chan, W. C.; Park, C.-M. Expedient Synthesis of Highly Substituted Pyrroles via Tandem Rearrangement of a-Diazo Oxime Ethers. J. Am. Chem. Soc. 2012, 134, 4104-4107.

(6) Loy, N. S. Y.; Kim, S. and Park, C.-M. Synthesis of Unsymmetrical Pyrazines Based on α-Diazo Oxime Ethers. Org. Lett. 2015, 17, 395-397.

(7) (a) Leonard, N. J.; Zwanenburg, B. Small Charged Rings. IX. Expansion of the Azirine Ring. J. Am. Chem. Soc. 1967, 89, 4456-4465. (b) Pusch, S.; Opatz, T. A Photochemical One-Pot Three-Component Synthesis of Tetrasubstituted Imidazoles. Org. Lett. 2014, 16, 5430-5433.

(8) (a) Taber, D. F.; Tian, W. W. The Neber Route to Substituted Indoles. J. Am. Chem. Soc. 2006, 128, 1058-1059. (b) Jana, S.; Clements, M. D.; Sharp, B. K.; Zheng, N. Fe(II)-Catalyzed Amination of Aromatic C-H Bonds via Ring Opening of 2H-Azirines: Synthesis of 2,3-Disubstituted Indoles. Org. Lett. 2010, 12, 3736-3739. (c) Thangaraj, M.; Bhojgude, S. S.; Jain, S.; Gonnade, R. G.; Biju, A. T. Selective Synthesis of N-Unsubstituted and N-Arylindoles by the Reaction of Arynes with Azirines. J. Org. Chem. 2016, 81, 8604-8611.

(9) (a) Chen, F.; Shen, T.; Cui, Y.; Jiao, N. 2,4- vs 3,4-Disubsituted Pyrrole Synthesis Switched by Copper and Nickel Catalysts. Org. Lett. 2012, 14, 4926-4929. (b) Li, T.; Xin, X.; Wang, C.; Wang, D.; Wu, F.; Li, X.; Wan, B. Cu-Catalyzed Ring Opening Reaction of 2H-Azirines with Terminal Alkynes: An Easy Access to 3-Alkynylated Pyrroles.

Org. Lett. 2014, 16, 4806-4809. (c) Zhu, L.; Yu, Y.; Mao, Z.; Huang, X. Gold-Catalyzed Intermolecular Nitrene Transfer from 2H-Azirines to Ynamides: A Direct Approach to Polysubstituted Pyrroles. Org. Lett. 2015, 17, 30-33. (d) Wang, Y.; Lei, X.; Tang, Y. Rh(II)-Catalyzed Cycloadditions of 1-Tosyl 1,2,3-triazoles with 2H-Azirines: Switchable Reactivity of Rh-azavinylcarbene as [2C]- or aza-[3C]-synthon. Chem. Commun. 2015, 51, 4507-4510. (e) Zhao, M.-N.; Ren, Z.-H.; Yang, D.-S. and Guan, Z.-H. Iron-Catalyzed Radical Cycloaddition of 2H-Azirines and Enamides for the Synthesis of Pyrroles. Org. Lett. 2018, 20, 1287.

(10) (a) Loy, N. S. Y.; Singh, A.; Xu, X.; Park, C.-M. Synthesis of Pyridines by Carbenoid-Mediated Ring Opening of 2H-Azirines. Angew. Chem., Int. Ed. 2013, 52, 2212-2216. (b) Jiang, Y.; Park, C.-M.; Loh, T.-P. Transition-Metal-Free Synthesis of Substituted Pyridines via Ring Expansion of 2-Allyl-2H-azirines. Org. Lett. 2014, 16, 3432-3435.

(11) (a) Ryu, T.; Baek, Y.; Lee, P. H. Synthesis of Pyrazines from Rhodium-Catalyzed Reaction of 2H-Azirines with N-Sulfonyl 1,2,3-Triazoles. J. Org. Chem. 2015, 80, 2376-2383. (b) Ding, H.; Wang, Z.; Bai, S.; Lu, P.; Wang, Y. Rh-Catalyzed Conversion of 3-Diazoindolin-2-imines to 5H-Pyrazino[2,3-b]indoles with Photoluminescent Properties. Org. Lett. 2017, 19, 6514-6517. (c) Baek, Y.; Maeng, C.; Kim, H. Lee, P. H. Regioselective Synthesis of Indolopyrazines through a Sequential Rhodium-Catalyzed Formal [3+3] Cycloaddition and Aromatization Reaction of Diazoindolinimines with Azirines. J. Org. Chem. 2018, 83, 2349-2360.

(12) Benzimidate substrates which we have used the for the Co(III)catalyzed C-H activation. Gong, S.; Xi, W.; Ding, Z. and Sun. H. Synthesis of Isoquinolines from Benzimidates and Alkynes via Cobalt(III)-Catalyzed C-H Functionalization/Cyclization. J. Org. Chem. 2017, 82, 7643-7647.

(13) Crystallographic data for 3aa has been deposited with the Cambridge Crystallographic Data Centre as deposition numbers CCDC 1861288. Detailed information can be found in the Supporting Information

(14) Yadav, V. K.; Babu, K. G. A Remarkably Efficient Markovnikov Hydrochlorination of Olefins and Transformation of Nitriles into Imidates by Use of AcCl and an Alcohol. Eur. J. Org. Chem. 2005, 2005, 452-456.

(15) (a) Loy, N. S. Y.; Singh, A.; Xu, X. and Park, C.-M. Synthesis of Pyridines by Carbenoid-Mediated Ring Opening of 2H-Azirines. Angew. Chem., Int. Ed. 2013, 52, 2212-2216. (b) Loy, N. S. Y.; Kim, S. and Park, C.-M. Synthesis of Unsymmetrical Pyrazines Based on α-Diazo Oxime Ethers. Org. Lett. 2015, 17, 395-397.